Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AKP-009 in benign prostatic hyperplasia
jRCT2031250037Phase 2Active, not recruiting
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ludaterone acetate in benign prostatic hyperplasia (BPH) (3 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoint: Percent change from baseline in prostate volume at Week 24. Started Apr 2025; status: active, not recruiting.
02
Drugs
ludaterone acetate
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on jRCT2031250037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250037.